Physiomics Regulatory News (PYC)

21 October 2019

Physiomics plc

("Physiomics") or (the "Company")

Dispatch of Annual Report and Notice of AGM

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens, is pleased to announce that it has today posted to shareholders its Annual Report and Accounts for the financial year ended 30 June 2019 together with its Notice of Annual General Meeting ("AGM").

As previously announced on the 30 September 2019, the Company's AGM will be held at 10.00 a.m. on 19 November 2019 at the Company's registered office, The Magdalen Centre, Oxford Science Park, Robert Robinson Avenue, Oxford, OX4 4GA.

A copy of the Notice of AGM, containing further details of the resolutions, as well as a copy of the Company's Annual Report and Accounts will be made available today on the Company's website at www.physiomics.co.uk/investors/reports-prospectus/.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.